Immunotherapy as first treatment for stomach cancer
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests immunotherapy as the first treatment for people with advanced or locally advanced stomach cancer. It may help if you haven't had any prior anti-cancer therapy and are starting treatment soon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have advanced or locally advanced gastric cancer
- You haven't received any previous anti-cancer treatments like chemotherapy or immunotherapy
- You are expected to start immunotherapy as your first or neoadjuvant therapy
- You have a good performance status (able to do daily activities without major help)
- Your organs are working well enough (like liver, kidneys, and bone marrow)
- You do not have a weak immune system or an autoimmune disease (like lupus or rheumatoid arthritis)
- You do not have an active serious infection (like tuberculosis) or need strong antibiotics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving immunotherapy before surgery can help shrink advanced stomach cancer and improve outcomes. Immunotherapy uses your body's own immune system to fight cancer cells.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) as a first treatment for stomach cancer that cannot be removed by surgery. The goal is to see if this combination can shrink the tumor enough to allow surgery later.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests giving an immunotherapy drug before surgery to see if it can increase immune cells in the tumor and improve outcomes for people with advanced stomach cancer. It may help shrink the tumor and make surgery more effective.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.